隐匿性乙型肝炎病毒感染研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.029

摘要/Abstract

摘要： 血清HBsAg阴性,但肝组织或血清HBV DNA长期存在,这种状态被称为隐匿性HBV感染（OBI）。由于实际HBV流行率和病毒流行株的地域性差异、所选取的研究人群的差异和不同检测方法的敏感性和特异性的差异,不同研究所得到的OBI的流行率有很大的差别。OBI的形成机制尚未完全阐明,可能有多种病毒学因素、宿主因素参与其中。OBI能通过输血、分娩和肝移植等方式进行传播,引起新发感染。当宿主免疫功能下降或应用免疫抑制性药物时,OBI可以复燃,恢复经典的血清学表现。OBI引起的轻微但持续的坏死性炎症可以促进肝脏疾病的进展,并且可以通过直接或者间接的机制增加肿瘤的发生风险。临床上需要建立更敏感的检测方法诊断OBI,以减少OBI相关的潜在威胁,帮助医师合理采取治疗措施,延缓病情进展。

关键词: 乙型肝炎, 隐匿性HBV感染, HBsAg, 肝细胞癌

Abstract: Occult hepatitis B virus （HBV） infection （OBI） is defined as the status with persistent serum HBsAg negative, but with serum/intrahepatic HBV DNA positive. Due to the differences in prevalence of HBV infection,prevalent viral strains, study samples,as well as sensitivity and specificity of methodology,the available data of OBI prevalence quite varied. The pathogenesis of OBI has not been fully elucidated. It is a complex process involving multiple virological and host factors. OBI can be transmitted through blood transfusion,parturition and liver transplantation to cause de novo infection. Immune dysfunction andapplication of immunosuppressive agents can lead to OBI reactivation and recurrence of typical serological evidence. The slight but persistent necro-inflammation can promote the progression of liver disease and increase the risk of tumorigenesis. In clinic,more sensitive detection methods are needed for diagnosis of OBI to reduce OBI-related potential threat and help clinicians to take reasonable managements to slow the progression of the disease.

Key words: Hepatitis B virus, Occult hepatitis B virus infection, Hepatitis B virus surface antigens, Hepatocellular carcinoma

陈建宏, 刘妍, 李进, 徐东平. 隐匿性乙型肝炎病毒感染研究进展^*[J]. 实用肝脏病杂志, 2015, 18(2): 205-208.

Chen Jianhong, Liu Yan, Li Jin, Xu Dongping. Occult hepatitis B virus infection: Present and future[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 205-208.

参考文献

[1] Hoofnagle JH,minary results of HBV DNA testing of Polish haemophillia patients-lack of occult HBV infection. Haemophillia,2006,12（4）:380-383.
[5] Rinonce HT,Yano Y,Utsumi T,et al. Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta,Indomesia:Prevalence and molecular evidence for nosocomial transmission.J Med Virol,2013,85（8）:1348-1361.
[6] Wong DK,Huang FY,Lai CL,et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology,2011,54（3）:829-836.
[7] Minuk GY,Sun DF,Uhanova J,et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol,2005,42（4）:480-485.
[8] Ireland JH,OHeland JB,Basuni AA,et al. Ractivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology,2000,31（5）:1176-1182.
[9] Bes M,Vargas V,Piron M,et al. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol,2012,56（4）:765-774.
[10] Feitelson MA,Lee J. Hepatitis B virus integration, fragile sites,and hepatocarcinogenesis. Cancer Lett,2007,252（2）:157-170.
[11] Huang CH,Yuan Q,Chen PJ, et al.Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol,2012,57（4）:720-729.
[12] Biswas S,Candotti D,Allain JP. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. J Virol,2013,87（14）:7882-7892.
[13] Kim BK,Choi SH,Chung SH,et al. Pre-S mutations of hepatitis B virus affect genome replicationand expression of surface antigens. J Gastroenterol Hepatol,2014,29（4）:843-850.
[14] Yu DM, Li XH,Mom V,et al. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. J Hepatol,2014,60（3）:515-522.
[15] Coffin CS,Pham TNQ,Mulrooney PM,et al. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology,2004,40（5）:1053-1061.
[16] Pollicino T,Raffa G,Costantino L,et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology,2007,45（2）:277-285.
[17] Lucifora J,Durantel D,Testoni B,et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology,2010,51（1）:63-72.
[18] Portela A,Esteller M. Epigenetic modifications and human disease. Nature Biotechnol,2010,28（10）:1057-1068.
[19] Vivekanandan P,Thomas D,Torbenson M. Methylation regulates hepatitis B viral protein expression.J Infect Dis,2009,199（9）:1286-1291.
[20] Pollicino T,Belloni L,Raffa G,et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA bound H3 and H4 histones. Gastroenterology,2006,130（3）:823-837.
[21] Conjeevaram HS,Lok AS. Occult hepatitis B virus infection:a hidden menace. Hepatology,2001,34（5）:204-206.
[22] Zhu W,Wu C,Deng W,et al. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS one,2012,7（9）:e45146.
[23] Bellecave P,Gouttenoire J,Gajer M,et al. Hepatitis B and C virus coinfection:a novel model system reveals the absence of direct viral interference. Hepatology,2009,50（1）:46-55.
[24] McClary H,Koch R,Chisari FV,et al. Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med,2000,192（2）:289-294.
[25] Coppola N,Loquercio G,Tonziello G,et al. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol,2013,58（1）:315-317.
[26] Raimondo G,Caccamo G,Filomia R,et al. Occult HBV infection. Semin Immunopathol,2013,35（1）:39-52.
[27] Pande C,Sarin SK,Patra S,et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies:a randomized controlles trial. J Viral Hepat,2013,20（11）:801-810.
[28] Yeo W,Chan TC,Leung NW,et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B,undergoing anticancer therapy with or without rituximab.J Clin Oncol,2009,27（4）:605-611.
[29] Squadrito G,Cacciola I,Alibrandi A,et al. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol,2013,59（4）:696-700.
[30] Ikeda K,Kobayashi M,Someya T,et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B,non-C liver cirrhosis:A cohort study. J Viral Hepat,2009,16（6）:437-443.
[31] Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection:Epidemiology,clinicalfeatures,viralinteractionsand treatment. J Gastroenterol Hepatol,2008,23（4）:512-520.
[32] Stroffolini T,Almasio PL,Persico M,et al. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol,2008,103（8）:1966-1972.
[33] Boyault S,Rickman DS,de Reyniès A,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology,2007,45（1）:42-52.
[34] Huang X,Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma:a systematic review. J Viral Hepat,2014,21（3）:153-162.
[35] Chen CH,Changchien CS,Lee CM,et al. A study on sequence variations in pre-S/surface,X and enhancer II/core promoter /precore regions of occult hepatitis B virus in non-B,non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer,2009,125（3）:621-629.

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[8]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[9]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[10]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[11]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[12]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[13]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[14]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[15]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.

隐匿性乙型肝炎病毒感染研究进展^*

Occult hepatitis B virus infection: Present and future

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价